HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism
The aim of this study is to identify new targets in cholesterol metabolism thanks to a
 genetically-based strategy.
The goal is to recruit 400 subjects: 200 adult subjects with familial hypobetalipoproteinemia
 (FHBL) (index cases) plus 200 additional related subjects in at least 10 large informative
 FHBL families, in which there is no known mutation in FHBL genes.

 The patient care is modified: patient will have an Hospital Anxiety and Depression (HAD)
 questionnaire (focus on depressive syndrome), a food diary, and some additional blood
 analysis (including genetic analysis).

 One of the main issue to recruit FHBL patients is the fact that they are asymptomatic and
 that FHBL is not identified as a serious illness by their general physicians.

 Step-1. Excluding mutations in selected candidate genes As a first approach to screen
 candidate genes and exclude patients with known mutations, the investigators developed a
 custom design based on the Haloplex™ technology (Agilent® Technologies) to perform
 high-throughput sequencing of the coding regions of 10 genes, including those previously
 described in FHBL (apolipoprotein B (APOB), Proprotein convertase subtilisin/kexin type 9
 (PCSK9)), Microsomal triglyceride transfer protein (MTP or ABL), chylomicron retention
 disease (CMRD), Secretion associated, Ras related GTPase (SARA2 gene), as well as 6
 additional candidate genes in cholesterol metabolism (low density lipoprotein receptor
 (LDLR), Sortilin (SORT1), Inducible Degrader of the LDL receptor (IDOL), Cholesteryl ester
 transfer protein (CETP), Apolipoprotein E (ApoE) and Angiopoietin-like Protein 3 (ANGTPL3)).
 All the recruited index cases (n=200) will be genotyped to select only those without
 mutations in previously described genes, being approximately 50% of our index case cohort.

 Step-2. Identification of informative families and exome sequencing In patients without
 identified mutations, the investigators will conduct a familial screening in order to
 identify other cases of FHBL among proband relatives. An analysis of fasting plasma lipid
 parameters (total cholesterol (TC), High density lipoprotein cholesterol (HDL-C), Low-Density
 Lipoproteins (LDL-C) and triglycerides (TG)) will be performed for each related. Affected
 subjects will be determined by a spontaneous LDL-C < 80 mg/dl and/or apoB < 50 mg/dl. In
 contrast, non-affected subjects will display LDL-C > 80 mg/dl and/or apoB > 50 mg/dl.

 For large families, the investigators will then combine whole-exome sequencing and linkage
 analysis to identify any novel genetic variant likely explaining FHBL. Depending on family
 pedigree, whole-exome sequencing (WES) will be performed on 2 to 5 patients per family. All
 relatives will be genotyped for linkage analysis.

 In parallel to this genetic approach, a regional epidemiological analysis will be performed
 to identify some geographical clusters with a high prevalence of the disease, as developed in
 the project named VaCaRMe (for Vascular and Cardiac, Respiratory and Metabolic overcome
 diseases)

 An additional aim, based on an exhaustive phenotyping of FHBL patients, is to investigate the
 safety of very low LDL-C and to perform some genotype-phenotype correlations in patients with
 FHBL population."
Inclusion Criteria:

 -  For index cases without family screening:

 o Patient with HBL: fasting LDL-C ≤ 50 mg/dl.

 -  For familial affected cases:

 -  Relative with HBL: fasting LDL-C ≤ 80 mg/dl and/or Apo B ≤ 50 mg/dl and at least
 one related family case suffering from HBL.

 All subjects, including familial non-affected cases, must give written consent (dated and
 signed) to participate at the constitution of biobank (including DNA samples and urine
 samples).

 Exclusion Criteria:

 -  Use of lipid-lowering drugs (statins, fibrates, ezetimibe, bile-acid sequestering
 resin) or nutraceuticals known to affect lipids (red yeast rice, margarine and dairy
 with plant sterol)

 -  Patient screened within an extreme metabolic disturbance (emergency situations,
 sepsis, hospitalization in intensive care unit)

 -  Patients with hyperthyroidism, severe liver failure, end stage chronic kidney disease,
 serious pancreatic failure, anemia related to thalassemia or sickle cell disease,
 strict vegan diet or malnutrition

 -  Refusal of the patient or his legal representative to participate in the study"